IL17A and rheumatoid arthritis: Similar results were found in humans where dual inhibition of TNFα and IL-17A with ABT-122 was shown to have a similar efficacy and safety profile to that of the TNFi alone in trials of rheumatoid arthritis and psoriatic arthritis [64] with limited real-life reports of highlighted an enhanced side effect risk profile in resistant SpA [65].